In a bid to bolster its oncology pipeline, Eli Lilly has entered into a collaboration agreement with Magnet Biomedicine to discover, develop and commercialise molecular glue therapeutics in oncology. The deal, which is worth up to US$1.29 B, provides Lilly with access to Magnet’s TrueGlue discovery platform to develop and advance molecular glue therapeutics to address unmet medical needs. This deal places Lilly in competition with other big pharmaceutical players that are also heavily investing in the molecular glue space, such as AbbVie, Novo Nordisk, and Eisai.